In the field of Health, the American FDA (Food and Drug Administration) has just authorized a application very interesting that would generate insulin injections.
In Belgium, you should know that 8% of the population is diabetic. This corresponds to approximately 1 million Belgians affected. 30% undiagnosed. Over the age of 65, one in 10 Belgians has type 2 diabetes, but one in two has not been screened. The program was developed on iOS and Android by Tandem Diabetes Careand is connected to the t:slim X2™ insulin pump marketed by the latter (and which is available in Belgium in specialized stores).
How does it work ?
Pump therapy is quite simple. Indeed, the insulin pump is a small electronic device, regarding the size of a mobile phone, which can be carried easily on the belt, in the pocket, or even attached to a strap of a bra. It can thus be almost invisible, which makes it a very discreet therapy. Thanks to this application, users will be able to “schedule or cancel dose injections” directly from their iPhone. Previously, l’application was more passive and was only used to monitor variations or provide histories. Tandem Diabetes Care wish make this feature available to its existing users at no additional cost. It should start rolling out this spring with test groups, with a full launch later in the summer.
Arrival in Europe subject to several authorizations
The point currently pending is whether this version can also be authorized on the European market by the reference organizations. And above all, in what timeframe. As a reminder, applications are submitted to the competent European authority, namely the European Medicines Agency (EMA) in the European Union or nationally such as the Federal Agency for Medicines and Health Products (AFMPS).
We know that Apple puts a lot for health through the various sensors and accessories made available to these users. This FAD approval comes as Apple itself is reportedly investigating potential diabetes treatment technology for the Apple Watch. Although Apple’s roadmap in this area is ambitious, more recent reports have claimed that the company has encountered several obstacles in its path.
